Jones Financial Companies
NKTR icon

Jones Financial Companies’s Nektar Therapeutics NKTR Stock Holding History

Jones Financial Companies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Buy
346
+46
+15% +$3.37K ﹤0.01% 3460
2026
Q1 		$20.6K Buy
300
+191
+175% +$10.9K ﹤0.01% 3281
2025
Q4 		$4.61K Sell
109
-6
-5% -$336 ﹤0.01% 3541
2025
Q3 		$6.73K Buy
115
+22
+24% +$728 ﹤0.01% 3247
2025
Q2 		$2.4K Buy
93
+33
+55% +$371 ﹤0.01% 3407
2025
Q1 		$668 Buy
60
+33
+122% +$431 ﹤0.01% 3476
2024
Q4 		$372 Buy
+27
New +$476 ﹤0.01% 3262

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jones Financial Companies's NKTR Position: Q2 2026 in Review

Jones Financial Companies increased its Nektar Therapeutics (NKTR) stake by 15% in Q2 2026, buying an estimated $3.37K and bringing the position to 346 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

Jones Financial Companies first reported a position in NKTR in Q4 2024 and has held it in 7 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Jones Financial Companies held 346 shares of Nektar Therapeutics worth $22K as of Q2 2026.
  • Jones Financial Companies bought 46 Nektar Therapeutics shares in Q2 2026, an estimated $3.37K.
  • Nektar Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3460 holding.
  • Jones Financial Companies first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.